Skip to main content
Elahe Mostaghel, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

ElaheAMostaghelMD

Oncology Seattle, WA

Assistant Professor, Medicine, University of Washington School of Medicine

Dr. Mostaghel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mostaghel's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - Present
  • WA State Medical License
    WA State Medical License 2003 - 2025

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations  
    Elahe Mostaghel, MD, Clinical Cancer Research
  • Contribution of Adrenal Glands to Intra-Tumor Androgens and Growth of Castration Resistant Prostate Cancer  
    Alvin M Matsumoto, Maria S Tretiakova, Lawrence True, Elahe A Mostaghel, Clinical Cancer Research
  • Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer  
    Elahe Mostaghel, MD, Clinical Cancer Research

Press Mentions

  • Oral Relugolix Works to a T Against Advanced Prostate Cancer
    Oral Relugolix Works to a T Against Advanced Prostate CancerMay 30th, 2020
  • Context Partners with Research Institutions to Study Sigma1 Protein in Treatment of Fibrosis, Cancer
    Context Partners with Research Institutions to Study Sigma1 Protein in Treatment of Fibrosis, CancerAugust 21st, 2017

Grant Support

  • In Vivo Efficacy Of Multi-Targeted Androgen Inhibition As Prostate Cancer TherapyNational Cancer Institute2006–2010

Professional Memberships

Hospital Affiliations